Tumax Deepwise Unveils Four AI-Powered Diagnostic Solutions at CCR 2018
On November 9, the 2018 Chinese Congress of Radiology (CCR2018) grandly opened at the China National Convention Center in Beijing. As a leading global enterprise in medical artificial intelligence, TomoDeep held a new product launch event at the CCR conference, unveiling four innovative intelligent diagnostic technologies: the Intelligent Chest X-ray Diagnostic System (σ-Discover/Lung DR), the Intelligent Mammography Diagnostic System (σ-Discover/Mammo), the Intelligent Stroke CT Diagnostic System (σ-Discover/Stroke CT), and the Intelligent Liver CT Diagnostic System (σ-Discover/Liver CT).
Hong Nan, Assistant to the President of Peking University People’s Hospital and Director of the Department of Radiology; Shi Yuxin, Vice President of Shanghai Public Health Clinical Center Affiliated to Fudan University; Yan Fuhua, Director of the Department of Radiology at Ruijin Hospital, Shanghai Jiao Tong University School of Medicine; Lu Jianping, Director of the Department of Imaging Medicine at Changhai Hospital Affiliated to Naval Medical University; Hu Hongjie, Director of the Medical Imaging Center at Sir Run Run Shaw Hospital, Zhejiang University School of Medicine; Huang Yi, General Manager of CT Products for GE Healthcare Greater China; and Bennett Landman, Professor in the Department of Electrical Engineering and Computer Science at Vanderbilt University, among other top experts, attended the Tuma Shenwei product launch event. Together with Zhong Xin, Founder and CEO of Tuma Shenwei, and Gao Dashan, Co-founder and CTO, they jointly participated in the launch ceremony for Tuma Shenwei’s new products.
Professor Liu Shiyuan, President-Elect of the Chinese Society of Radiology, Chairman of the China Medical Imaging AI Industry-Academia-Research-Application Innovation Alliance, and Director of the Department of Diagnostic and Interventional Radiology and Nuclear Medicine at Shanghai Changzheng Hospital, also attended the Deepwise press conference to provide guidance and engaged in cordial discussions with Deepwise CEO Zhong Xin. We extend our sincere gratitude to Professor Liu for his encouragement and recognition of Deepwise.
In his address, Zhong Xin stated, “Today, we are unveiling four new artificial intelligence diagnostic systems, following our σ-Discover/Lung Nodule intelligent diagnostic system. These new products represent significant advancements in both architecture and performance. Through this presentation, we aim to highlight our key progress in medical AI and bolster confidence within the medical AI industry. We look forward to working hand in hand with our strategic partners—including GE, NVIDIA, Alibaba Health, Lianzhong, and Yingsi—as well as all friends present here, to contribute to the development of medical artificial intelligence and advance China’s healthcare sector. Our ultimate goal is to truly integrate technology into everyday life and create a better future through innovation.”
Zhong Xin, Founder and CEO of Tumor Deep Vision
In August 2017, Tuma Shenwei launched its first intelligent diagnostic product—the Discover/Lung Nodule Intelligent Diagnostic System for pulmonary nodules. Since its release over a year ago, the system has been deployed in nearly 200 hospitals. Building on this strong foundation, Tuma Shenwei has now consecutively released four new intelligent products: the Chest X-ray Intelligent Diagnostic System (σ-Discover/Lung DR), the Mammography Intelligent Diagnostic System (σ-Discover/Mammo), the Stroke CT Intelligent Diagnostic System (σ-Discover/Stroke CT), and the Liver CT Intelligent Diagnostic System (σ-Discover/Liver CT). Focusing on real clinical needs and pain points, these solutions cover the entire workflow, including disease monitoring, quantitative analysis, disease classification, benign/malignant differentiation, follow-up tracking, and report generation, providing physicians with precise auxiliary diagnostic tools.
Tumashenwei Vice President Wu Gang Introduced Four New Smart Products at the Launch Event
(σ-Discover/Lung DR): Designed for thoracic DR imaging, this system enables automatic detection and localization of 15 types of chest diseases, with a sensitivity exceeding 90%. It automatically identifies various pathologies and accurately distinguishes healthy individuals, thereby enhancing physicians' workflow efficiency. Equipped with benign and malignant risk assessment capabilities, it boosts diagnostic confidence among clinicians.
(σ-Discover/Mammo): Designed for mammographic imaging, with a sensitivity of over 95% for calcifications and over 90% for masses. It intelligently identifies breast lesions and enables precise lesion localization. The system adheres to BI-RADS guidelines, providing a basis for clinical treatment.
(σ-Discover/StrokeCT): Rapidly detects acute hemorrhagic and ischemic lesions in CT images, determining their location, volume, risk level, and other parameters to establish a clear diagnosis and treatment plan during the critical window for emergency care, while also providing prognostic assessment.
(σ-Discover/Liver CT): Automatically performs liver segmentation based on CT images, intelligently detects hepatic lesions, and provides information such as the location and volume of conditions including hepatic nodules, liver cirrhosis, and fatty liver. The benign and malignant lesion assessment function guides prognostic evaluation based on the LI-RADS classification.
Wu Gang stated that Tuma Shenwei’s four new AI-powered products are currently undergoing clinical trials in hospitals. Other products, including AI diagnostic systems for prostate cancer, fractures, and diabetic retinopathy, are in intensive development. This series of products focuses on areas with high incidence rates among Chinese patients, such as tumors, cardiovascular and cerebrovascular diseases, and chronic diseases, and has been customized specifically for the Chinese patient population. In the future, Tuma Shenwei plans to release 3–5 new products annually to rapidly achieve full-process diagnostic coverage for multiple body parts, while simultaneously strengthening its expansion into overseas markets, including the United States, Europe, Japan, and Southeast Asia.
“By expanding its range of covered diseases, Tuma Shenwei has achieved a value leap from radiology to clinical practice. This robust AI-assisted diagnosis and treatment system will become the infrastructure of the entire intelligent healthcare industry and serve as a key component of Tuma Shenwei’s integrated smart service platform, which combines research, genomics, and pharmaceuticals,” introduced Wu Gang.
Since its inception, Tumra Shenwei has relied on the strong support of medical experts both in China and abroad. At this new product launch event, Tumra Shenwei has specially invited numerous experts to attend in person, jointly witnessing the company’s dedication and growth.
Assistant to the President of Peking University People's Hospital and Director of the Department of Radiology, Hong Nan:
Peking University People’s Hospital has maintained an ongoing collaboration with TomoDeep. The fact that TomoDeep was able to invite top-tier experts to gather at this product launch event underscores the widespread recognition of its products. We have long anticipated that TomoDeep would introduce more intelligent diagnostic solutions with distinctive features, and indeed, four new products were unveiled today. Demonstrating both capability and a commitment to tangible results, TomoDeep is expected to continue providing high-quality products to clinicians in the future.
Shi Yuxin, Deputy Director of the Public Health Clinical Center Affiliated to Fudan University:
As living standards continue to rise, there is growing demand for early diagnosis and treatment of diseases. The public expects consistent, high-quality medical care; however, high-caliber physician resources are limited. Artificial intelligence offers a promising solution to achieving standardized healthcare. TomoDeep has seized this opportunity and contributed to China’s healthcare reform. Our hospital has had the privilege of trialing TomoDeep’s newly released product, which has alleviated physicians’ workload and improved diagnostic accuracy. We hope that TomoDeep’s products will become increasingly user-friendly and intelligent.
Yan Fuhua, Director of the Department of Radiology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine:
AI has been a hot topic at this year’s CCR. It is crucial for AI products to be closely aligned with clinical practice and to provide genuine assistance to physicians. The several products recently launched by Tuma Shenwei all focus on high-incidence diseases and tumors. I believe that in-depth research and clinical integration of AI products will help physicians improve diagnostic accuracy, thereby better benefiting patients and society. I look forward to Tuma Shenwei launching more products in the future, allowing us to reap the benefits brought by AI. I wish Tuma Shenwei continued success in its development.
Lu Jianping, Director of the Department of Radiology, Changhai Hospital Affiliated to Naval Medical University:
The four products released by Tumor Deep Vision cover the most common and troubling issues for both patients and doctors in the medical community. We believe these products will better address various challenges faced by physicians and patients, and we wish Tumor Deep Vision continued success and further advancements.
Hu Hongjie, Director of the Medical Imaging Center at Sir Run Run Shaw Hospital, Zhejiang University School of Medicine:
We have been collaborating with TomoDeep for the past two to three years and have received substantial support. TomoDeep’s pulmonary nodule products have gained increasing acceptance among radiologists. Today, we are delighted to see the launch of four new products. We hope that a growing range of solutions will help radiologists reduce their workload and improve diagnostic accuracy, ultimately benefiting a broad patient population. AI has become an unstoppable trend, and we hope TomoDeep will play a pivotal role in this process, leading industry development.
Huang Yi, General Manager of CT Products, GE Healthcare Greater China:
During the promotion of low-dose lung cancer screening, GE encountered challenges such as massive data volumes and difficulties in retrieving patient data. AI has provided highly effective tools to address these issues. We expect our partner, TomoDeep, to bring more advanced technologies to market, thereby serving medical research and the general public.
Bennett Landman, Professor in the Department of Electrical Engineering and Computer Science at Vanderbilt University:
I am thrilled to be here today as an expert in the AI algorithms industry. Algorithms constitute one of the most fundamental pillars of artificial intelligence. Recently, we have achieved remarkable milestones in the AI field. We maintain a close partnership with DeepWise Medical, focusing on leveraging comprehensively learned medical imaging data for multi-organ segmentation and disease classification. Looking ahead, we will deepen our collaborative research on foundational algorithms and clinical radiological diagnostics. It is a great privilege to engage in such a close collaboration with DeepWise Medical.
In recent years, artificial intelligence (AI) has been widely applied in the healthcare sector, bringing transformative impacts to traditional medical systems and making health care delivery more efficient. Recently, the Political Bureau of the Communist Party of China Central Committee held a group study session on the current status and trends of AI development, underscoring that AI is becoming a key driving force in the new round of technological revolution and industrial transformation.
Tumavision’s latest product release adopts cutting-edge methods from the fields of deep learning and artificial intelligence, including 3D convolution-based deep adversarial generative networks and universal model training. By extracting shareable information from diverse data sources, it enables the simultaneous application of a single network model across multiple scenarios, significantly improving the efficiency of model training and computation. This approach effectively addresses the challenges of class imbalance in medical data and incomplete data annotation, establishing a first-mover advantage through frontier technologies.
Tumashenwei’s products are protected by independent intellectual property rights, having secured multiple invention patents and software copyrights in both the United States and China, with more than 20 academic papers published in renowned international conferences and journals in the medical field.
As it translates its technological advantages into product leadership, Tuma Shenwei has become a strategic partner of companies such as GE Healthcare, NVIDIA, Alibaba Health, Union Medical, and Yingsi, collaborating across various aspects including product development and implementation to jointly drive the rapid development of intelligent healthcare in China.
Tumashenwei is leveraging its technological prowess and market capabilities to build a moat for high-quality corporate development, bringing intelligent diagnostic products that genuinely enhance medical efficiency and address clinical challenges to market.